Analysts rate LogicBio Therapeutics Inc. (LOGC:NSD) with a Strong Buy rating and a $3.25 target

Chardan Capital maintains the $2.5 LOGC stock price target and rates it as a Buy.

Based on the LogicBio Therapeutics stock forecast from 2 analysts, the average analyst LOGC stock price target is USD 3.25 over the next 12 months. LogicBio Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of LOGC stock forecast is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, LogicBio Therapeutics stock price was USD 2.01LogicBio Therapeutics stock price has changed by +1.72% over the past week, +1.65% over the past month and -54.52% over the last year.

LogicBio Therapeutics stock forecast from 4 Crowd Analysts, has the average Crowd  Analyst LOGC stock price target at USD 2.25 over the next 12 months. LogicBio Therapeutics Inc’s average Crowd rating is Strong Buy.


About LogicBio Therapeutics Inc. (LOGC:NSD):

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children’s Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.


Latest Analyst Ratings for LOGC:

Maintains Chardan Capital Buy USD 4 » USD 2.5 2022-08-22
Maintains Chardan Capital Buy USD 6 » USD 4 2022-05-17
Upgraded by William Blair Market Perform » Outperform 2022-05-09
Downgrades William Blair Market Perform 2022-02-03
Maintains Chardan Capital Hold USD 16 » USD 6 2022-02-02
Target Lowered by Chardan Capital Buy USD 20 » USD 16 2021-12-23
Target Lowered by Barclays Overweight USD 24 » USD 8 2021-11-17
Target Lowered by JMP Securities Market Outperform USD 17 » USD 16
Reiterated by JMP Securities Buy USD 17 2021-09-27
Initiated by HC Wainwright Buy USD 15 2021-06-07
Reiterated by Chardan Capital Buy USD 20 2021-06-02
Initiated by JMP Securities Outperform USD 17 2021-03-04
Reiterates William Blair Buy 2019-11-12
Reiterates Chardan Capital Buy 2019-07-29
Initiated Roth Capital Buy USD 26 2019-05-01
Initiates William Blair Outperform » Outperform USD 26 2018-11-13
Initiated Barclays Overweight USD 24 2018-11-13
Initiates Coverage On Chardan Capital Buy USD 20 2018-11-13


What we like:

Underpriced compared to book value:

LOGC stock price is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow:

LogicBio Therapeutics had positive total free cash flow in the most recent four quarters.


What we don’t like:

Low market capitalization:

LOGC stock is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns:

LogicBio Therapeutics is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns, the returns are unpredictable. Proceed with caution.

Below median dividend returns:

The average income yield of LOGC stock over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow:

LogicBio Therapeutics had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis:

LOGC stock price is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth:

LOGC stock has shown below median earnings growth in the previous 5 years compared to its sector.